All In Biotech

Drug Trial Radar · NCT02547571

The Bowel CLEAnsing: A National Initiative

Last checked: Nov 20, 2026Latest source record: Sep 13, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 3,476 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,476

Actual

Start

Mar 2016

Primary completion

Sep 2018

Study completion Sep 2018

Sponsor

Lead sponsor
Alan BarkunAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Pendopharm
First posted
Sep 11, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare diet, type of bowel preparation and time of colonoscopy to determine if one method is better than the other and, if they are the same, identify the one which is the most convenient for the patients.

Conditions

  • Subjets Requiring a Colonoscopy

Interventions

  • High volume PEG split-doseDrug

    Colyte® or PegLyte® will be provided to the subject who will be asked to drink 2L of the preparation starting at 7:00 PM the day before the procedure at a rate of 240 mL every 10 minutes until completed. The second dose of 2L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the planned procedural time at a rate of 240 mL every 10 minutes until completed.

  • Low volume PEG split-doseDrug

    Bi-PegLyte® will be provided to the subject who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure. After the first bowel movement, or if there is no bowel movement within 6 hours of taking the Bisacodyl tablets, the subject will be asked to drink 1L of the solution at a rate of 240 mL every 10 minutes until the solution is completed. The second dose of 1L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the procedure at a rate of 240 mL every 10 minutes. Use of antacids will not be permitted within one hour of taking bisacodyl.

  • High volume PEG non split, day beforeDrug

    Colyte® or PegLyte® will be provided to the subject who will be asked to drink 4L of preparation starting at 6:00 PM the day before the procedure, at a rate of 240 mL every 10 minutes until completed.

  • Low volume PEG non split, same dayDrug

    Bi-PegLyte® will be provided to the subject, who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure and will drink 2L of preparation the morning of the colonoscopy starting 4 hours prior to the procedure at a rate of 240 mL every 10 minutes, until completed. Use of antacids will not be permitted within one hour of taking Bisacodyl.

  • Clear liquid dietOther

  • Low residue dietOther

  • Early colonoscopy (stratified)Other

    "Early" appointments: 7:30 AM to 10h30 AM

  • Later colonoscopy (stratified)Other

    "Later" appointments: 10:30 AM to 4:30 PM.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Bowel cleansing according to the Boston ScaleTime frame: Day of colonoscopy

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Hôpital St-Sacrement, CHU de Québec-Université Laval

    Québec, Canada

  • Forzani & MacPhail Colon Cancer Screening Centre

    Calgary, Alberta, Canada

  • University of Alberta Hospital

    Edmonton, Alberta, Canada

  • St. Paul's Hospital

    Vancouver, British Columbia, Canada

  • Health Sciences center and St. Boniface Hospital

    Winnipeg, Manitoba, Canada

  • QEII HSC

    Halifax, Nova Scotia, Canada

  • Western University

    London, Ontario, Canada

  • The Ottawa Hospital

    Ottawa, Ontario, Canada

  • CHUM

    Montreal, Quebec, Canada

  • McGill University Health Centre

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.